Literature DB >> 29745872

Effects of autonomic dysfunction on exercise tolerance in systemic sclerosis patients without clinical and instrumental evidence of cardiac and pulmonary involvement.

Marcello Di Paolo1, Antonietta Gigante2, Marta Liberatori3, Liborio Sardo3, Paolo Marinelli1, Marco Rossetti1, Paolo Palange1, Luigi Tubani3, Edoardo Rosato3.   

Abstract

OBJECTIVES: Autonomic dysfunction (AD) in systemic sclerosis (SSc) was already confirmed through heart rate variability (HRV) analysis. Cardio-pulmonary exercise testing (CPET) is a useful tool in early detection of exercise tolerance in SSc patients. Aim of the study was to assess the relationships existing between AD and exercise tolerance.
METHODS: Thirty-two [4 M, 28 F; median age: 47.5 (20-65) years] consecutive SSc patients were enrolled. All patients underwent pulmonary function testing, incremental symptom-limited CPET and twenty-four hours ECG Holter recording with HRV analysis in time and frequency domain. Multiple regression analysis was performed in order to identify independent HRV predictors of exercise tolerance and cardiac efficiency during the effort.
RESULTS: HRV analysis showed significant differences in power in low and high frequency (LF and HF, respectively) and their ratio (LF/HF) compared to healthy controls. Nocturnal ratio be- tween power in low and high frequency at HRV (LF/HFnight) was shown to be the only independent positive predictor of maximal work load (R2=18.6%, p=0.014) and maximal oxygen consumption (V' O2 peak) expressed both as absolute value (R2=24.2%, p=0.004) and as corrected for body weight (R2=21.6%, p=0.007). A positive linear relationship was also found between nocturnal LF (LFnight) and the oxygen uptake/work rate (V'O2/W) slope (R2=15.8%, p=0.024).
CONCLUSIONS: In SSc patients without cardiopulmonary involvement AD is associated with better exercise tolerance and cardiac function during physical effort. Further studies are needed to confirm these results.

Entities:  

Mesh:

Year:  2018        PMID: 29745872

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

1.  Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement.

Authors:  Francesco Iannazzo; Chiara Pellicano; Amalia Colalillo; Cesarina Ramaccini; Antonella Romaniello; Antonietta Gigante; Edoardo Rosato
Journal:  Clin Exp Med       Date:  2022-07-25       Impact factor: 5.057

2.  Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis.

Authors:  Alessandro Santaniello; Rosa Casella; Marco Vicenzi; Irene Rota; Gaia Montanelli; Maria De Santis; Chiara Bellocchi; Federico Lombardi; Lorenzo Beretta
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.